Fig. 8: Antitumor efficacy of combination TAK-931 and ICI treatment in the J558 mouse allograft model. | Nature Communications

Fig. 8: Antitumor efficacy of combination TAK-931 and ICI treatment in the J558 mouse allograft model.

From: CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade

Fig. 8

a Experimental schemes of antitumor efficacy studies with combination TAK-931 and ICI treatment in J558 mouse syngeneic model. b–e Antitumor efficacy of single-agent TAK-931 or ICI treatment in J558-allograft model. The J558-allograft mice were orally administered with TAK-931, Vehicle: CR = 0/10, TAK-931: CR = 2/10 b or intraperitoneally with m-PD-1, Vehicle: CR = 0/10, TAK-931: CR = 2/10 c, m-PD-L1, Vehicle: CR = 0/10, TAK-931: CR = 1/10 d, m-CTLA-4, Vehicle: CR = 0/10, TAK-931: CR = 1/10 e at the indicated regimen. Black and red indicate vehicle and the indicated drug treatments, respectively. Data are shown as tumor volumes (mm3); n = 10. f–h Antitumor efficacy of combination treatment with TAK-931 and ICIs in J558-allograft model. The J558-allograft mice were administered with m-PD-1, Vehicle: CR = 0/10, TAK-931: CR = 6/10 f, m-PD-L1, Vehicle: CR = 0/10, TAK-931: CR = 3/10 g, or m-CTLA-4, Vehicle: CR = 0/10, TAK-931: CR = 7/10 h in combination with TAK-931 at the indicated regimen. Black and red indicate vehicle and the indicated drug treatments, respectively. The efficacy data are plotted as tumor volumes (mm3); n = 10. i–k Preclinical Kaplan–Meier survival curves at 1200 mm3 of the endpoint tumor volume. Antitumor efficacy results of m-PD-1 and TAK-931 i, m-PD-L1 and TAK-931 j, and m-CTLA-4 and TAK-931 k in the J558-allograft model are shown. l Summary of the antitumor efficacy studies in combination treatment in J558-allograft model. Source data are provided as a Source Data file.

Back to article page